Pharmacokinetic evaluation of continuous intravenous epoprostenol

Bibliography

• Bos C, Richel D, Ritsema T, Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004;36(7):1187-205
   PubMed Web of Science ®Google Scholar
• Vane J, Corin R. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg 2003;26(6):571-8
   PubMed Web of Science ®Google Scholar
• Vane J, Anggard E, Botting R. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323(1):27-36
   PubMed Web of Science ®Google Scholar
• McLaughlin V, McGoon M. Pulmonary arterial hypertension. Circulation 2006;114(13):1417-31
   PubMed Web of Science ®Google Scholar
• Rubin L. Primary pulmonary hypertension. N Engl J Med 1997;336(2):111-17
   PubMed Web of Science ®Google Scholar
• Christman B, McPherson C, Newman J, An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327(2):70-5
   PubMed Web of Science ®Google Scholar
• Moncada S, Gryglewski R, Bunting S, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263(5579):663-5
   PubMed Web of Science ®Google Scholar
• Whittaker N, Bunting S, Salmon J, The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976;12(6):915-28
   PubMedGoogle Scholar
• Gryglewski R. Prostaglandins, platelets, and atherosclerosis. CRC Crit Rev Biochem 1980;7(4):291-338
   PubMedGoogle Scholar
• Vane J, Botting R. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995;75(3):3A-10A
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31(4):891-901
   PubMed Web of Science ®Google Scholar
• Vane J, Bakhle Y, Botting R. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120
   PubMed Web of Science ®Google Scholar
• Marcus A, Weksler B, Jaffe E, Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980;66(5):979-86
   PubMed Web of Science ®Google Scholar
• Bunting S, Gryglewski R, Moncada S, Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976;12(6):897-913
   PubMedGoogle Scholar
• Langleben D, Barst R, Badesch D, Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 1999;99(25):3266-71
   PubMed Web of Science ®Google Scholar
• Prins B, Hu R, Nazario B, Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994;269(16):11938-44
   PubMed Web of Science ®Google Scholar
• Fetalvero K, Martin K, Hwa J. Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat 2007;82(1-4):109-18
   PubMed Web of Science ®Google Scholar
• Wharton J, Davie N, Upton P, Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000;102(25):3130-6
   PubMed Web of Science ®Google Scholar
• Li R, Cindrova-Davies T, Skepper J, Prostacyclin induces apoptosis of vascular smooth muscle cells by a cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogenic activity of endothelin-1 or basic fibroblast growth factor. Circ Res 2004;94(6):759-67
   PubMed Web of Science ®Google Scholar
• Moncada S, Vane J. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978;30(3):293-331
   PubMed Web of Science ®Google Scholar
• Kothapalli D, Stewart S, Smyth E, Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol 2003;64(2):249-58
   PubMed Web of Science ®Google Scholar
• Clapp L, Finney P, Turcato S, Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26(2):194-201
   PubMed Web of Science ®Google Scholar
• Sinzinger H, Fitscha P, Kritz H. Antimitotic actions of vasodilatory prostaglandins – clinical aspects. Agents Actions Suppl 1997;48:92-106
   PubMedGoogle Scholar
• Olschewski H, Olschewski A, Rose F, Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001;138(5):287-97
   PubMedGoogle Scholar
• Zardi E, Zardi D, Cacciapaglia F, Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. Int Immunopharmacol 2005;5(3):437-59
   PubMed Web of Science ®Google Scholar
• Araki H, Lefer A. Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res 1980;47(5):757-63
   PubMed Web of Science ®Google Scholar
• Ogletree M, Lefer A, Smith J, Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol 1979;56(1-2):95-103
   PubMed Web of Science ®Google Scholar
• Montalescot G, Drobinski G, Meurin P, Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 1998;82(6):749-55
   PubMed Web of Science ®Google Scholar
• Rich S, McLaughlin V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34(4):1184-7
   PubMed Web of Science ®Google Scholar
• Wauthy P, Abdel Kafi S, Mooi W, Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension. J Thorac Cardiovasc Surg 2003;126(5):1434-41
   PubMed Web of Science ®Google Scholar
• Rex S, Missant C, Segers P, Epoprostenol treatment of acute pulmonary hypertension is associated with a paradoxical decrease in right ventricular contractility. Intensive Care Med 2008;34(1):179-89
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79(4):1193-226
   PubMed Web of Science ®Google Scholar
• Adie E, Mullaney I, McKenzie F, Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma x glioma cells to prostanoid agonists. Quantification and functional implications. Biochem J 1992;285(Pt 2):529-36
   PubMedGoogle Scholar
• Hartshorne D, Ito M, Erdodi F. Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil 1998;19(4):325-41
   PubMed Web of Science ®Google Scholar
• Wise H. Multiple signalling options for prostacyclin. Acta Pharmacol Sin 2003;24(7):625-30
   PubMed Web of Science ®Google Scholar
• Abramovitz M, Adam M, Boie Y, The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000;1483(2):285-93
   PubMed Web of Science ®Google Scholar
• Hatae T, Wada M, Yokoyama C, Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 2001;276(49):46260-7
   PubMed Web of Science ®Google Scholar
• Walch L, Labat C, Gascard J, Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol 1999;126(4):859-66
   PubMed Web of Science ®Google Scholar
• Tuder R, Cool C, Geraci M, Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159(6):1925-32
   PubMed Web of Science ®Google Scholar
• Geraci M, Gao B, Shepherd D, Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999;103(11):1509-15
   PubMed Web of Science ®Google Scholar
• Tahara N, Kai H, Niiyama H, Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum Gene Ther 2004;15(12):1270-8
   PubMed Web of Science ®Google Scholar
• Friedman R, Mears J, Barst R. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997;96(9):2782-4
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Pullamsetti SS, Breitenbach SC, Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res 2007;8:4
   PubMedGoogle Scholar
• Smyth E, Austin S, Reilly M, Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 2000;275(41):32037-45
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Genthner D, Panella M, Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338(5):273-7
   PubMed Web of Science ®Google Scholar
• Benedict N, Seybert A, Mathier M. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007;29(10):2134-53
   PubMed Web of Science ®Google Scholar
• Brash A, Jackson E, Saggese C, Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 1983;226(1):78-87
   PubMed Web of Science ®Google Scholar
• Herner S, Mauro L. Epoprostenol in primary pulmonary hypertension. Ann Pharmacother 1999;33(3):340-7
   PubMed Web of Science ®Google Scholar
• Witchey-Lakshmanan L, Palepu N, Teja BB. A novel formulation of epoprostenol with antimicrobial properties, administered under ambient conditions, for treatment of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:A3364
   Google Scholar
• Laliberte K, Arneson C, Jeffs R, Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44(2):209-14
   PubMed Web of Science ®Google Scholar
• Mubarak K. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010;104(1):9-21
   PubMed Web of Science ®Google Scholar
• Hoeper M, Schwarze M, Ehlerding S, Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342(25):1866-70
   PubMed Web of Science ®Google Scholar
• Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986;30(1):61-8
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002;20(4):1037-49
   PubMed Web of Science ®Google Scholar
• Barst R, McGoon M, McLaughlin V, Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-25
   PubMed Web of Science ®Google Scholar
• Galie N, Humbert M, Vachiery J, Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39(9):1496-502
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper M, Humbert M, Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34(6):1219-63
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper M, Humbert M, Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30(20):2493-537
   PubMedGoogle Scholar
• Montani D, O'Callaghan D, Jais X, Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. Eur Respir Rev 2009;18(114):231-49
   Google Scholar
• Badesch D, McLaughlin V, Delcroix M, Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):56S-61S
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Wheeldon D, Wells F, Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1(8385):1046-7
   PubMed Web of Science ®Google Scholar
• Rubin L, Mendoza J, Hood M, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112(7):485-91
   PubMed Web of Science ®Google Scholar
• Barst R, Rubin L, McGoon M, Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121(6):409-15
   PubMed Web of Science ®Google Scholar
• Barst R, Rubin L, Long W, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302
   PubMed Web of Science ®Google Scholar
• Shapiro S, Oudiz R, Cao T, Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30(2):343-9
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40(4):780-8
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106(12):1477-82
   PubMed Web of Science ®Google Scholar
• Badesch D, Tapson V, McGoon M, Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132(6):425-34
   PubMed Web of Science ®Google Scholar
• Humbert M, Sanchez O, Fartoukh M, Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999;13(6):1351-6
   PubMed Web of Science ®Google Scholar
• Klings E, Hill N, Ieong M, Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999;42(12):2638-45
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Genthner D, Panella M, Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999;130(9):740-3
   PubMed Web of Science ®Google Scholar
• Rosenzweig E, Kerstein D, Barst R. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99(14):1858-65
   PubMed Web of Science ®Google Scholar
• Kuo P, Johnson L, Plotkin J, Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63(4):604-6
   PubMed Web of Science ®Google Scholar
• Krowka M, Frantz R, McGoon M, Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30(3):641-8
   PubMed Web of Science ®Google Scholar
• Aguilar R, Farber H. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162(5):1846-50
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Sitbon O, Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167(10):1433-9
   PubMed Web of Science ®Google Scholar
• Cabrol S, Souza R, Jais X, Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007;26(4):357-62
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Butt A, McMahon A, Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80(2):151-5
   PubMed Web of Science ®Google Scholar
• Montani D, Price L, Dorfmuller P, Pulmonary veno-occlusive disease. Eur Respir J 2009;33(1):189-200
   PubMed Web of Science ®Google Scholar
• Montani D, Jais X, Price L, Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009;34(6):1348-56
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351(14):1425-36
   PubMed Web of Science ®Google Scholar
• Humbert M, Barst RJ, Robbins IM, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24(3):353-9
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin L, Galie N, Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149(8):521-30
   PubMed Web of Science ®Google Scholar
• Barst R, Berman-Rosenzweig E, Horn E. Bloodstream infections among patients treated with intravenous eporpostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. Morb Mortal Wkly Rep 2007;56:170-2
   PubMedGoogle Scholar
• Kallen A, Lederman E, Balaji A, Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008;29(4):342-9
   PubMed Web of Science ®Google Scholar
• Zaccardelli D, Phares K, Jeffs R, Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan. Int J Clin Pract 2010;64(7):885-91
   PubMed Web of Science ®Google Scholar
• Oudiz R, Widlitz A, Beckmann X, Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 2004;126(1):90-4
   PubMed Web of Science ®Google Scholar
• O'Callaghan DS, Moutet A, Jais X, Catheter realted-infections in pulmonary hypertension patients treated by continuous intravenous epoprostenol: experience if the French Referral Centre. Am J Respir Crit Care Med 2010;181:A3337
   Google Scholar
• Doran A, Ivy D, Barst R, Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008;(160):5-9
   PubMedGoogle Scholar
• Kingman M, Tankersley M, Lombardi S, Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. J Heart Lung Transplant 2010;29(8):841-6
   PubMed Web of Science ®Google Scholar
• Chin K, Channick R, de Lemos J, Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest 2009;135(1):130-6
   PubMed Web of Science ®Google Scholar
• Magnani B, Galie N. Prostacyclin in primary pulmonary hypertension. Eur Heart J 1996;17(1):18-24
   PubMed Web of Science ®Google Scholar
• Ahearn G, Selim M, Tapson V. Severe erythroderma as a complication of continuous epoprostenol therapy. Chest 2002;122(1):378-80
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Pieton R, Sieradzki J, The effects of prostacyclin on glycemia and insulin release in man. Prostaglandins 1980;19(6):959-68
   PubMedGoogle Scholar
• Montani D, Achouh L, Dorfmuller P, Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008;87(4):220-33
   PubMed Web of Science ®Google Scholar
• Montani D, O'Callaghan DS, Savale L, Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med 2010;104:S23-32
   PubMed Web of Science ®Google Scholar
• Huang S, DeSantis E. Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm 2007;64(18):1922-6
   PubMed Web of Science ®Google Scholar
• Bedard E, Dimopoulos K, Gatzoulis M. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009;30(3):256-65
   PubMed Web of Science ®Google Scholar
• Bildirici I, Shumway J. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery. Obstet Gynecol 2004;103(5 Pt 2):1102-5
   PubMed Web of Science ®Google Scholar
• Stewart R, Tuazon D, Olson G, Pregnancy and primary pulmonary hypertension: successful outcome with epoprostenol therapy. Chest 2001;119(3):973-5
   PubMed Web of Science ®Google Scholar
• Price L, Montani D, Jais X, Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J 2010;35(6):1294-302
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Gaine S, Barst R, Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41(2):293-9
   PubMed Web of Science ®Google Scholar
• Oudiz R, Farber H. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 2009;157(4):625-35
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Butt A, Dinh-Xaun A, Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998;79(2):175-9
   PubMed Web of Science ®Google Scholar
• Jacobs W, Vonk-Noordegraaf A. Epoprostenol in pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol 2009;5(1):83-90
   PubMed Web of Science ®Google Scholar